TheraRadar
Clinical-Stage Companies / Circassia Limited

Circassia Limited

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 5/1/2016

24
Total Trials
3
Phase 3
19
Phase 2
0
Recruiting
209
Score

Pipeline by Phase

Phase 3
3
Phase 2
19
Phase 1
4

Therapeutic Focus

Cat Allergy Rhinoconjunctivitis Seasonal Allergic Rhinitis Allergy Rhinitis

Clinical Trials (24)

NCT01620762 Phase 3 COMPLETED

Phase III Cat-PAD Study

Started: 10/1/2012

NCT02040844 Phase 3 COMPLETED

Phase III Cat-PAD Follow-on Study

Started: 2/1/2014

NCT02150343 Phase 2 COMPLETED

Phase II HDM-SPIRE Safety and Efficacy Study

Started: 9/1/2014

NCT01921257 Phase 2 COMPLETED

Paediatric Safety Study in Cat-PAD

Started: 8/1/2013

NCT02478060 Phase 2 COMPLETED

Birch-SPIRE Safety and Efficacy Study

Started: 7/1/2015

NCT02795273 Phase 2 WITHDRAWN

Efficacy and Safety of Grass-SPIRE Registration Study

Started: 5/1/2016

NCT02161107 Phase 2 COMPLETED

Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma

Started: 4/1/2014

NCT02061709 Phase 2 COMPLETED

Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber

Started: 1/1/2014

NCT02061670 Phase 2 COMPLETED

Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma

Started: 1/1/2014

NCT01949441 Phase 2 COMPLETED

ToleroMune House Dust Mite (HDM) Tolerability Study

Started: 9/1/2013

NCT01385800 Phase 2 COMPLETED

ToleroMune Grass Exposure Unit Study

Started: 8/1/2011

NCT01447784 Phase 2 COMPLETED

ToleroMune House Dust Mites (HDM) Exposure Chamber Study

Started: 9/1/2011

NCT01361412 Phase 2 COMPLETED

Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy

Started: 3/1/2011

NCT01198613 Phase 2 COMPLETED

ToleroMune Ragweed Exposure Chamber Study

Started: 9/1/2010

NCT01166061 Phase 2 COMPLETED

Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis

Started: 7/1/2010

NCT01008332 Phase 2 COMPLETED

Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis

Started: 11/1/2009

NCT00878774 Phase 2 COMPLETED

Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis

Started: 4/1/2009

NCT01033344 Phase 2 COMPLETED

Cat-PAD Exposure Chamber Study

Started: 1/1/2010

NCT00867906 Phase 2 COMPLETED

Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma

Started: 3/1/2009

NCT00729508 Phase 2 COMPLETED

Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects

Started: 8/1/2008

NCT01383603 Phase 1 COMPLETED

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis

Started: 10/1/2011

NCT01383590 Phase 1 COMPLETED

Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis

Started: 10/1/2011

NCT01743118 Phase 1 COMPLETED

Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

Started: 3/1/2013

NCT00685711 Phase 1 COMPLETED

Safety of Cat-PAD in Cat Allergic Subjects

Started: 1/1/2008

Drug Candidates

Cat-PAD Placebo Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762] Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762] Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762] HDM-SPIRE Birch-SPIRE Grass-SPIRE Ragweed-SPIRE ToleroMune HDM
Activity Status: Inactive
Last Trial Started: 5/1/2016
Last Trial Ended: 5/1/2017
Trials (12 months): 0
Completed Trials: 23
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.